Number of participants reporting an adverse event · people with eczema
Atopiclair showed no clear difference in number of participants reporting an adverse event compared with vehicle (moderate certainty).
1 finding from 1 review
Change from baseline in disease severity as assessed by the investigators · people with eczema
1 finding from 1 review
Number of participants who experienced a flare · people with eczema
Atopiclair probably leads to lower number of participants who experienced a flare compared with vehicle (moderate certainty).
1 finding from 1 review
Change in use of topical active treatment ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Change from baseline in health‐related quality of life ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Change from baseline in disease severity according to participants ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants who rated treatment satisfaction as good to excellent · people with eczema
1 finding from 1 review
Number of participants reporting an adverse event · people with eczema
1 finding from 1 review
Change from baseline in disease severity as assessed by the investigators · people with eczema
1 finding from 1 review
Number of participants who experienced a flare · people with eczema
1 finding from 1 review
Change in use of topical active treatment ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Change from baseline in quality of life ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Change from baseline in disease severity as assessed by the participants (number of participants reporting good to excellent result) · people with eczema
Vehicle treatment + daily moisturiser leads to lower change from baseline in disease severity as assessed by the… compared with fluticasone propionate twice weekly + daily moisturiser (high certainty).
1 finding from 1 review
Participant satisfaction ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants reporting an adverse event · people with eczema
Vehicle treatment + daily moisturiser showed no clear difference in number of participants reporting an adverse event compared with fluticasone propionate twice weekly + daily moisturiser (low certainty).
1 finding from 1 review
Change from baseline in disease severity as assessed by the investigators · people with eczema
1 finding from 1 review
Number of participants who experienced a flare · people with eczema
Vehicle treatment + daily moisturiser probably leads to higher number of participants who experienced a flare compared with fluticasone propionate twice weekly + daily moisturiser (moderate certainty).
1 finding from 1 review
Change in use of topical active treatment ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Change from baseline in quality of life ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review
Change from baseline in disease severity according to participants ‐ not measured · people with eczema
The review found no eligible studies for this question.
1 finding from 1 review